This Article Full Text Full Text (PDF) Erratum (v26,p820) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Armstrong, A. J. Articles by Eisenberger, M. Search for Related Content PubMed PubMed Citation Articles by Armstrong, A. J. Articles by Eisenberger, M. Related Articles Related Correspondence Social Bookmarking                            What's this?

Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer

Andrew J. Armstrong, Elizabeth Garrett-Mayer, Yi-Chun Ou Yang, Michael A. Carducci, Ian Tannock, Ronald de Wit, Mario Eisenberger

From the Duke Comprehensive Cancer Center, Durham, NC; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD; Department of Medical Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada; and the Department of Medical Oncology, Rotterdam Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands

Address reprint requests to Andrew J. Armstrong, MD, ScM, DUMC Box 3850, Durham, NC 27710; e-mail: andrew.armstrong{at}duke.edu

Purpose It is currently unclear if early prostate-specific antigen (PSA) or pain improvements are adequate surrogates for overall survival in men with metastatic hormone-refractory prostate cancer (HRPC). Here we examined various degrees of PSA decline and pain response as surrogates for the survival benefit observed in the TAX327 trial.

Patients and Methods In the TAX327 trial, 1,006 men with HRPC were randomly assigned to receive docetaxel in two schedules, or mitoxantrone, each with prednisone: 989 men provided data on 3-month PSA decline. Surrogacy was examined for post-treatment changes in PSA and pain response using Cox proportional hazards models to calculate the proportion of treatment effect (PTE) explained by each potential surrogate.

Results A 30% PSA decline within 3 months of treatment initiation provides the highest degree of surrogacy, with a PTE of 0.66 (95% CI, 0.23 to 1.0), and was associated with a hazard ratio (HR) of 0.50 (95% CI, 0.43 to 0.58) for overall survival after adjusting for treatment effect. Introduction of a 30% PSA decline is predictive of survival regardless of treatment arm. Other changes in PSA or PSA kinetics, PSA normalization, and pain responses were highly prognostic but weaker surrogates for survival.

Conclusion In the TAX327 trial, a PSA decline of 30% within 3 months of chemotherapy initiation had the highest degree of surrogacy for overall survival, confirming data from the Southwest Oncology Group 9916 trial. However, given the wide CIs around the estimate of this moderate surrogate effect, overall survival should remain the preferred end point for phase III trials of cytotoxic agents in HRPC.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Are Prostate-Specific Antigen Changes Valid Surrogates for Survival in Hormone-Refractory Prostate Cancer? A Meta-Analysis Is Needed!
  Laurence Collette, Marc Buyse, and Tomasz Burzykowski
  JCO 2007 25: 5673-5674 [Full Text]

This article has been cited by other articles:

				A. J. Armstrong and P. G. Febbo Using Surrogate Biomarkers to Predict Clinical Benefit in Men with Castration-Resistant Prostate Cancer: An Update and Review of the Literature Oncologist, August 1, 2009; 14(8): 816 - 827. [Abstract] [Full Text] [PDF]

				J. Michels, S. L. Ellard, L. Le, C. Kollmannsberger, N. Murray, E. S. Tomlinson Guns, R. Carr, and K. N. Chi A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer Ann. Onc., July 24, 2009; (2009) mdp311v1. [Abstract] [Full Text] [PDF]

				G. Sonpavde, P. O. Periman, D. Bernold, D. Weckstein, M. T. Fleming, M. D. Galsky, W. R. Berry, F. Zhan, K. A. Boehm, L. Asmar, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy Ann. Onc., July 24, 2009; (2009) mdp323v1. [Abstract] [Full Text] [PDF]

				S. Halabi, N. J. Vogelzang, S.-S. Ou, K. Owzar, L. Archer, and E. J. Small Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer J. Clin. Oncol., June 10, 2009; 27(17): 2766 - 2771. [Abstract] [Full Text] [PDF]

				K. Fizazi, P. Beuzeboc, J. Lumbroso, V. Haddad, C. Massard, M. Gross-Goupil, M. Di Palma, B. Escudier, C. Theodore, Y. Loriot, et al. Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer J. Clin. Oncol., May 20, 2009; 27(15): 2429 - 2435. [Abstract] [Full Text] [PDF]

				S. Oudard, J. C. Eymard, and K. Fizazi Combining Docetaxel With Estramustine: Back to the Future? J. Clin. Oncol., March 1, 2009; 27(7): 1148 - 1149. [Full Text] [PDF]

				J.-P. Machiels, F. Mazzeo, M. Clausse, B. Filleul, L. Marcelis, B. Honhon, L. D'Hondt, C. Dopchie, V. Verschaeve, L. Duck, et al. Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer J. Clin. Oncol., November 10, 2008; 26(32): 5261 - 5268. [Abstract] [Full Text] [PDF]

				G. Attard, A. H.M. Reid, T. A. Yap, F. Raynaud, M. Dowsett, S. Settatree, M. Barrett, C. Parker, V. Martins, E. Folkerd, et al. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven J. Clin. Oncol., October 1, 2008; 26(28): 4563 - 4571. [Abstract] [Full Text] [PDF]

				G. Colloca, F. Checcaglini, and A. Venturino About sorafenib in castration-resistant prostate cancer Ann. Onc., October 1, 2008; 19(10): 1812 - 1813. [Full Text] [PDF]

				A. J. Armstrong, P. Creel, J. Turnbull, C. Moore, T. A. Jaffe, S. Haley, W. Petros, S. Yenser, J. P. Gockerman, D. Sleep, et al. A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6270 - 6276. [Abstract] [Full Text] [PDF]

				J. S. de Bono, H. I. Scher, R. B. Montgomery, C. Parker, M. C. Miller, H. Tissing, G. V. Doyle, L. W.W.M. Terstappen, K. J. Pienta, and D. Raghavan Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6302 - 6309. [Abstract] [Full Text] [PDF]

				I. E. Haines and R. M. Stanley Perspective on "Chemotherapy for Advanced Prostate Cancer: 25 Years Later": Is It a Mirage or an Oasis? J. Clin. Oncol., August 20, 2008; 26(24): 4049 - 4050. [Full Text] [PDF]

				G. Sonpavde, M. T. Fleming, T. E. Hutson, and M. D. Galsky Trial Design for Metastatic Castration-Resistant Prostate Cancer J. Clin. Oncol., July 20, 2008; 26(21): 3647 - 3648. [Full Text] [PDF]

				H. I. Scher, S. Halabi, I. F. Tannock, M. Morris, C. N. Sternberg, M. A. Carducci, M. A. Eisenberger, C. Higano, G. J. Bubley, R. Dreicer, et al. In Reply J. Clin. Oncol., July 20, 2008; 26(21): 3648 - 3649. [Full Text] [PDF]

				A. J. Armstrong, E. L. Garrett-Mayer, and M. Eisenberger Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens J Natl Cancer Inst, May 7, 2008; 100(9): 681 - 682. [Full Text] [PDF]

				D. R. Berthold, G. R. Pond, M. Roessner, R. de Wit, M. Eisenberger, a. I. F. Tannock, and on behalf of the TAX-327 investigators Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study Clin. Cancer Res., May 1, 2008; 14(9): 2763 - 2767. [Abstract] [Full Text] [PDF]

				M. E Buyse Surrogate Endpoints for Efficacy in Clinical Research: Working Definitions and Validation Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 659 - 663. [Abstract] [Full Text] [PDF]

				A. Berruti, M. Tucci, A. Mosca, M. Ardine, M. Poggio, A. Saini, L. Russo, F. Vana, and L. Dogliotti Could the Efficacy of Docetaxel in Prostate Cancer Patients Be Potentiated by Concomitant High-Dose Calcitriol Administration? J. Clin. Oncol., April 10, 2008; 26(11): 1900 - 1901. [Full Text] [PDF]

				T. M. Beer In Reply J. Clin. Oncol., April 10, 2008; 26(11): 1901 - 1902. [Full Text] [PDF]

				H. I. Scher, S. Halabi, I. Tannock, M. Morris, C. N. Sternberg, M. A. Carducci, M. A. Eisenberger, C. Higano, G. J. Bubley, R. Dreicer, et al. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group J. Clin. Oncol., March 1, 2008; 26(7): 1148 - 1159. [Abstract] [Full Text] [PDF]

				L. Collette, M. Buyse, and T. Burzykowski Are Prostate-Specific Antigen Changes Valid Surrogates for Survival in Hormone-Refractory Prostate Cancer? A Meta-Analysis Is Needed! J. Clin. Oncol., December 10, 2007; 25(35): 5673 - 5674. [Full Text] [PDF]

				A. J. Armstrong, E. Garrett-Mayer, M. Eisenberger, I. Tannock, and R. de Wit In Reply J. Clin. Oncol., December 10, 2007; 25(35): 5674 - 5674. [Full Text] [PDF]